266 related articles for article (PubMed ID: 10765090)
1. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group.
Roehrborn CG; Bruskewitz R; Nickel GC; Glickman S; Cox C; Anderson R; Kandzari S; Herlihy R; Kornitzer G; Brown BT; Holtgrewe HL; Taylor A; Wang D; Waldstreicher J
Eur Urol; 2000 May; 37(5):528-36. PubMed ID: 10765090
[TBL] [Abstract][Full Text] [Related]
2. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
Roehrborn CG; Bruskewitz R; Nickel JC; McConnell JD; Saltzman B; Gittelman MC; Malek GH; Gottesman JE; Suryawanshi S; Drisko J; Meehan A; Waldstreicher J;
J Urol; 2004 Mar; 171(3):1194-8. PubMed ID: 14767299
[TBL] [Abstract][Full Text] [Related]
3. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.
Kaplan S; Garvin D; Gilhooly P; Koppel M; Labasky R; Milsten R; Reddy P; Rosenberg S; Sussman D; White C; Lee M; Pappas F; Waldstreicher J
Urology; 2000 Oct; 56(4):610-6. PubMed ID: 11018616
[TBL] [Abstract][Full Text] [Related]
4. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
5. Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions.
Roehrborn CG
Urology; 2002 Jun; 59(6):811-5. PubMed ID: 12031358
[TBL] [Abstract][Full Text] [Related]
6. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
Logan YT; Belgeri MT
Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
[TBL] [Abstract][Full Text] [Related]
7. Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia.
Andersen JT; Nickel JC; Marshall VR; Schulman CC; Boyle P
Urology; 1997 Jun; 49(6):839-45. PubMed ID: 9187688
[TBL] [Abstract][Full Text] [Related]
8. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
9. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes.
Roehrborn CG; McConnell JD; Saltzman B; Bergner D; Gray T; Narayan P; Cook TJ; Johnson-Levonas AO; Quezada WA; Waldstreicher J;
Eur Urol; 2002 Jul; 42(1):1-6. PubMed ID: 12121721
[TBL] [Abstract][Full Text] [Related]
10. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
McConnell JD; Bruskewitz R; Walsh P; Andriole G; Lieber M; Holtgrewe HL; Albertsen P; Roehrborn CG; Nickel JC; Wang DZ; Taylor AM; Waldstreicher J
N Engl J Med; 1998 Feb; 338(9):557-63. PubMed ID: 9475762
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
12. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
Issa MM; Runken MC; Grogg AL; Shah MB
Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
Marberger MJ
Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous versus precipitated AUR: the same?
McNeil SA
World J Urol; 2006 Sep; 24(4):354-9. PubMed ID: 16738854
[TBL] [Abstract][Full Text] [Related]
15. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
[TBL] [Abstract][Full Text] [Related]
16. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Desgrandchamps F; De La Taille A; Doublet JD;
BJU Int; 2006 Apr; 97(4):727-33. PubMed ID: 16536763
[TBL] [Abstract][Full Text] [Related]
17. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
Boyle P; Roehrborn C; Harkaway R; Logie J; de la Rosette J; Emberton M
Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
[TBL] [Abstract][Full Text] [Related]
18. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
McNeill SA; Hargreave TB; Roehrborn CG;
Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
[TBL] [Abstract][Full Text] [Related]
19. Randomized controlled trial on the efficacy of bladder training before removing the indwelling urinary catheter in patients with acute urinary retention associated with benign prostatic hyperplasia.
Zhengyong Y; Changxiao H; Shibing Y; Caiwen W
Scand J Urol; 2014 Aug; 48(4):400-4. PubMed ID: 24697345
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.
Kaplan SA; Holtgrewe HL; Bruskewitz R; Saltzman B; Mobley D; Narayan P; Lund RH; Weiner S; Wells G; Cook TJ; Meehan A; Waldstreicher J;
Urology; 2001 Jun; 57(6):1073-7. PubMed ID: 11377309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
